Who may participate

Joining a clinical trial is an important and personal decision. Thank you for your interest in the AcRIS study. 

You may be eligible for the AcRIS study if you:

  • are relatively healthy,
  • have not received any doses of a COVID-19 vaccine,
  • have not received an RSV vaccine,
  • are not planning to get the COVID-19 or an RSV vaccine in the next 6-8 weeks,
  • are willing to complete daily voice recordings and respiratory symptom reporting via a phone app for 6-8 weeks,
  • are not participating in another study (other than the AcRIS study) that involves study medicines, devices, or other clinical therapies.  These are known as interventional studies.

There are other requirements for participation in the study. If you choose to download the app and start the process, more information about eligibility to take part is shared during prescreening and the informed consent process.

Healthy volunteers

The disease, disorder, syndrome, illness, or injury that is being studied. This study is limited to healthy individuals and no specific disease or disorder is under study.

18 and older

The age a person must be to participate in a clinical trial.

Male or Female

The sex of people who may participate in a clinical trial. Sex is a person's classification based on assignment at birth. Eligibility based on sex is distinct from eligibility based on gender.

COVID-19/RSV Vaccination Status
Have not received or plan to get a COVID-19 and RSV vaccine in the next 6-8 weeks

The COVID-19/RSV vaccination status of people who may participate in a clinical trial. COVID-19 and RSV vaccination status is based on a person’s receipt of any dose of any available COVID-19 and RSV vaccine.

Each clinical study has its own guidelines for who can participate, called eligibility criteria. However, only the research study staff can determine if you qualify to enroll in the study.

What to expect

If you choose to download the app and sign the informed consent, you will be asked health-related questions to see if you’re eligible to participate.  The AcRIS study is conducted virtually through a mobile phone app, with no in person visits. There is no study medicine given as part of the AcRIS study. You will take daily self-assessments in the app, including voice recordings and reporting of respiratory symptoms for about 8 weeks.

In addition, you will be sent two nasal swab self-collection kits. You will complete the first swab when the kit is received, and the second swab either when you report symptoms of respiratory illness or at the end of week 6 of your study participation. You will be provided your swab test results.

If you test positive for COVID-19, Influenza, or RSV on either swab, you will continue participating in the trial for 8 weeks. If both swabs are negative for all three viruses, your participation ends after week 6.

You will be compensated for your time to complete the daily study assessments if you choose to participate in the study.

Length of participation
About 6-8 weeks

Length of participation is the length of time the study participants will participate in the study.

Number of study visits
No in person study visits

Each clinical trial’s design specifies the number of study visits and the total length of the trial.

Daily, for about 2-4 minutes

This clinical trial includes self-assessments performed using an app on a smart phone.

Download the mobile app to see if you may qualify

You are not eligible to participate in the study if you have received any doses of a COVID-19 or RSV vaccine or if you are planning to get a COVID-19 or RSV vaccine in the next 6 to 8 weeks.

To see if you may qualify for the AcRIS study, you will begin by downloading the study app on either an iPhone® or AndroidTM mobile phone – the study app cannot be used on tablet devices. Once you’ve downloaded the app, you can complete the prescreener to determine if you are eligible. If you are eligible and choose to participate after reading the informed consent, you will complete daily study assessments using the app. The AcRIS study is conducted entirely through the mobile app and will not require you to visit a study clinic to participate.  Thank you for your consideration.



Apple store badge AcRIS

google app



App Store is a service mark of Apple Inc., registered in the U.S. and other countries.  Google Play and the Google Play logo are trademarks of Google LLC.

About COVID-19, Influenza, and RSV

Respiratory illnesses are often hard to distinguish because symptoms may be similar across different illnesses. This study is focusing on 3 illnesses: SARS-CoV-2, which is the strain of coronavirus that causes coronavirus disease 2019, also known as COVID-19; Influenza, which is commonly known as "the flu", and is an infectious disease caused by an influenza virus; and RSV, which is a common type of virus that can cause respiratory infection ranging from mild cold-like symptoms to severe lower respiratory tract disease.

Frequently Asked Questions

Will I need to go into a clinic to participate in this trial?

No, this trial is conducted entirely through a mobile app. Swabs are done by you, in your home and mailed away for testing.

Is this page helpful?

How many times per day do I need to take the self-assessment?

Self-assessments are completed once per day. These take about 2-4 minutes to complete.

Is this page helpful?

How long will I need to participate in the daily self-assessments?

Your participation will last between 6 and 8 weeks. You will be asked to take the self-assessments each day of your participation. The daily assessments are expected to take about 2-4 minutes to complete.

Is this page helpful?

Will I be paid for taking part in this study?

Yes, you will be compensated each day you complete all the assessments in the study app and for completing swab 1 and swab 2. If you are in the study for 6 weeks you will receive a total of $72, and $93 if you are in the study for 8 weeks.

Is this page helpful?

Do I need to send my self-swab kit to a lab?

Yes. The self-swab kit will come with detailed instructions on how to self-administer as well as how and where to send in the completed swab.

Is this page helpful?